Clinical Pharmacokinetics of Cyclophosphamide

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1979 Sep 1

PMID 389529

Citations 29

Authors

L B Grochow

M Colvin

Affiliations

Soon will be listed here.

Citing Articles

Cyclophosphamide-induced multiple organ dysfunctions: unravelling of dose dependent toxic impact on biochemistry and histology.

Sahu A, Mukherjee A, Nirala S, Bhadauria M Toxicol Res (Camb). 2024; 13(6):tfae201.

PMID: 39698395 PMC: 11650506. DOI: 10.1093/toxres/tfae201.

Oral cyclophosphamide-induced posterior reversible encephalopathy syndrome in a patient with ANCA-associated vasculitis: A case report.

Kim Y, Kwak J, Jung S, Lee S, Jang H, Cho H World J Clin Cases. 2021; 9(21):6130-6137.

PMID: 34368335 PMC: 8316926. DOI: 10.12998/wjcc.v9.i21.6130.

Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines .

Figueroa D, Asaduzzaman M, Young F Biomed Res Int. 2019; 2019:6146972.

PMID: 30766885 PMC: 6350544. DOI: 10.1155/2019/6146972.

Ginsenoside Rg1 improves bone marrow haematopoietic activity via extramedullary haematopoiesis of the spleen.

Liu H, Chen F, Liu R, Lin C, Chang K J Cell Mol Med. 2015; 19(11):2575-86.

PMID: 26153045 PMC: 4627563. DOI: 10.1111/jcmm.12643.

Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.

Zakka F, Chang P, Giuliari G, Foster C Clin Ophthalmol. 2009; 3:567-79.

PMID: 19898629 PMC: 2770868. DOI: 10.2147/opth.s4445.

References

Fenselau C, Kan M, Rao S, Myles A, Friedman O, Colvin M . Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res. 1977; 37(8 Pt 1):2538-43. View

Mouridsen H, Witten J, Frederiksen P, Hulsbaek I . Studies on the correlation between rate of biotransformation and haematological toxicity of cyclophosphamide. Acta Pharmacol Toxicol (Copenh). 1978; 43(4):328-30. DOI: 10.1111/j.1600-0773.1978.tb02274.x. View

Alberts D, Peng Y, Chen H, STRUCK R . Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. Br J Cancer. 1978; 38(2):316-24. PMC: 2009716. DOI: 10.1038/bjc.1978.204. View

Feil V, Lamoureux C . Alopecia activity of cyclophosphamide metabolites and related compounds in sheep. Cancer Res. 1974; 34(10):2596-8. View

Colvin M, Brundrett R, Kan M, Jardine I, Fenselau C . Alkylating properties of phosphoramide mustard. Cancer Res. 1976; 36(3):1121-6. View

Mullins G, Colvin M . Intensive cyclophosphamide (NSC-26271) therapy for solid tumors. Cancer Chemother Rep. 1975; 59(2 Pt 1):411-9. View

Donelli M, Vecchi A, Bossi A, Colombo T, Sironi M, Pantarotto C . Effect of phenobarbital on cyclophosphamide cytotoxic activity and pharmacokinetics in mice. Tumori. 1977; 63(2):137-46. DOI: 10.1177/030089167706300203. View

Mouridsen H, Faber O, SKOVSTED L . The biotransformation of cyclophosphamide in man: analysis of the variation in normal subjects. Acta Pharmacol Toxicol (Copenh). 1974; 35(2):98-106. DOI: 10.1111/j.1600-0773.1974.tb00729.x. View

Cohen J, Jao J . Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J Pharmacol Exp Ther. 1970; 174(2):206-10. View

10.

STRUCK R, Kirk M, Witt M, Laster Jr W . Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed Mass Spectrom. 1975; 2(1):46-52. DOI: 10.1002/bms.1200020109. View

11.

BERGSAGEL D, Robertson G, Hasselback R . Effect of cyclophosphamide on advanced lung cancer and the hematological toxicity of large, intermittent intravenous doses. Can Med Assoc J. 1968; 98(11):532-8. PMC: 1923907. View

12.

MELLETT L, Rall D, Adamson R . Metabolism of cyclophosphamide-C14 by various marine species. Arch Int Pharmacodyn Ther. 1969; 177(1):60-70. View

13.

Pantarotto C, Bossi A, Belvedere G, Martini A, Donelli M, Frigerio A . Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens. J Pharm Sci. 1974; 63(10):1554-8. DOI: 10.1002/jps.2600631014. View

14.

Weaver F, Torkelson A, Zygmunt W, BROWDER H . Tissue culture cytotoxicity assay for cyclophosphamide metabolites in rat body fluids. J Pharm Sci. 1978; 67(7):1009-12. DOI: 10.1002/jps.2600670738. View

15.

BROCK N, Gross R, HOHORST H, Klein H, Schneider B . Activation of cyclophosphamide in man and animals. Cancer. 1971; 27(6):1512-29. DOI: 10.1002/1097-0142(197106)27:6<1512::aid-cncr2820270636>3.0.co;2-q. View

16.

Alberts D, van Daalen Wetters T . The effect of allopurinol on cyclophosphamide antitumor activity. Cancer Res. 1976; 36(8):2790-4. View

17.

Facchinetti T, DIncalci M, Martelli G, Cantoni L, Belvedere G, Salmona M . Simple and sensitive method for the determination of cyclophosphamide by means of a nitrogen--phosphorus-selective detector. J Chromatogr. 1978; 145(2):315-8. DOI: 10.1016/s0378-4347(00)81355-9. View

18.

. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Boston Collaborative Drug Surveillance Program. JAMA. 1974; 227(9):1036-40. View

19.

Jao J, Jusko W, Cohen J . Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res. 1972; 32(12):2761-4. View

20.

Sladek N . Bioassay and relative cytotoxic potency of cyclophosphamide metabolites generated in vitro and in vivo. Cancer Res. 1973; 33(6):1150-8. View